Mootummaan UK sirna namootni koolugaltummaa gaafatanii oliyyannoo itti galfatan irrattii fooyya'insa gochuufi. Kaayyoonsaa ...

Regeneron has reported a phase 3 win in generalized myasthenia gravis, positioning the biotech to file for FDA approval of its siRNA candidate in the increasingly competitive neuromuscular disease.

The San Diego, USA firm has simultaneously announced that the US Food and Drug Administration (FDA) has granted Orphan Drug ...

Braemar Hotels & Resorts (BHR) announced on Tuesday an upsizing of its board of directors with the appointment of Bob Ghassemieh as a new member.

Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily ...

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

Pharmaceuticals announced that the primary and key secondary endpoints were met in the Phase 3 NIMBLE trial assessing ...

Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and announces that the U.S. Food and Drug Administration ...

Miidiyaan biyyaalessaa Kooriyaa Kaabaa akka gabaasanitti misaayeloonni ittisa haleellaa qilleensaa lama bakka hogganaan ...

Opening Day of the 2025 N.J. cross country is quickly approaching, which means teams will be gearing up their lineups to ...

A recent eGastroenterology review by Professor Intissar Anan highlights major breakthroughs in transthyretin amyloidosis ...